Key takeaways
Janumet (sitagliptin/metformin) and Onglyza (saxagliptin) are both medications used to treat Type 2 diabetes, but they have some key differences. Janumet is a combination of two drugs: sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide). Onglyza, on the other hand, contains only saxagliptin, which is also a DPP-4 inhibitor. Janumet is available in both extended-release and immediate-release forms, and is taken once or twice daily respectively. Onglyza is only taken once daily. Janumet can cause side effects like diarrhea and upper respiratory infections, whereas Onglyza may lead to urinary tract infections and headaches. Additionally, Janumet is not recommended for people with severe kidney problems. Janumet is only avaolable as a brand name medication, while Onglyza has a generic version available, making it potentially more affordable. Both medications can cause serious side effects like pancreatitis and heart failure, so it's important to discuss your medical history with your healthcare team.
